Recent immunotherapeutic approaches have evolved as powerful treatment options with
high anti-tumour responses involving the patient's own immune system. Passive …

Immunotherapy has transformed the treatment landscape of many cancers, with durable
responses in disease previously associated with a poor prognosis. Patient selection remains …

Purpose The goal of this guideline/procedure standard is to assist nuclear medicine
physicians, other nuclear medicine professionals, oncologists or other medical specialists …

Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced
malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However …

When evaluating metastatic tumor response to systemic therapies, dissociated response is
defined as the coexistence of responding and non-responding lesions within the same …

Background Reliable predictive and prognostic markers are still lacking for patients treated
with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC) …

Objective We aimed to identify imaging biomarkers to assess predictive capacity of
radiomics nomogram regarding treatment response status (responder/non-responder) in …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has made a
revolutionary difference in the treatment of malignant tumors, and considerably extended …

Immunotherapy by using immune checkpoint inhibitors is a revolutionary development in
oncology. Medical imaging is also impacted by this new therapy, particularly nuclear …

Purpose The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative …